Peter Kiener

Dr. Kiener is currently a Venture Partner at ICG Life Sciences. Peter is an industry veteran with extensive experience in both biologics and immunotherapy, and across the entire value chain of biopharmaceutical research and development. Peter was the former Chief Scientific Officer at Sucampo, until the company’s acquisition by Mallinckrodt in February 2018 . Prior to joining Sucampo, he served as CSO of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates. Prior to Ambrx, Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held executive leadership roles at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. He also worked on biologics for Bristol-Myers Squibb prior to his work at MedImmune. Peter has led or contributed to the development and approval of multiple drugs including antibodies, fusion proteins and vaccines. Dr. Kiener is a member of the Board of Directors of Cue Biopharma and Pieris.

Dr. Kiener earned a bachelor’s degree in chemistry from the University of Lancaster, UK and a doctorate of philosophy in biochemistry from the University of Oxford. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications.